Abstract
Over recent years, inflammasomes have emerged as key regulators of immune and inflammatory responses. They induce programmed cell death and direct the release of danger signals and the inflammatory cytokines interleukin (IL)-1β and IL-18. The concerted actions of inflammasomes are of utmost importance for responding adequately to harmful environmental agents and infections. However, deregulated inflammasome signaling is increasingly linked to a diversity of human pathologies, including rheumatoid arthritis, inflammatory bowel disease, and rare, hereditary periodic fever syndromes. In this review, we discuss recent insight in the protective and detrimental roles of inflammasomes in selected infectious, autoinflammatory and autoimmune diseases, and cover clinically approved therapies that interfere with inflammasome signaling. These findings highlight the importance of fine-balancing the Ying and Yang activities of inflammasomes for sustained homeostasis and suggest that further understanding of inflammasome mechanisms may offer new cures for human diseases.
Similar content being viewed by others
References
Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137–161
Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820
Broz P, von Moltke J, Jones JW, Vance RE, Monack DM (2010) Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe 8:471–483
Van Opdenbosch N, Gurung P, Vande Walle L, Fossoul A, Kanneganti TD, Lamkanfi M (2014) Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun 5:3209
Lamkanfi M, Dixit VM (2014) Mechanisms and functions of inflammasomes. Cell 157:1013–1022
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550
Lamkanfi M (2011) Emerging inflammasome effector mechanisms. Nat Rev Immunol 11:213–220
Brusselle GG, Provoost S, Bracke KR, Kuchmiy A, Lamkanfi M (2014) Inflammasomes in respiratory disease: from bench to bedside. Chest 145:1121–1133
Clay GM, Sutterwala FS, Wilson ME (2014) NLR proteins and parasitic disease. Immunol Res 59:142–152
Drummond RA, Gaffen SL, Hise AG, Brown GD (2014) Innate defense against fungal pathogens. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a019620
Chen I, Ichinohe T (2015) Response of host inflammasomes to viral infection. Trends Microbiol 23:55–63
Franchi L, Munoz-Planillo R, Nunez G (2012) Sensing and reacting to microbes through the inflammasomes. Nat Immunol 13:325–332
Bauernfeind F, Hornung V (2013) Of inflammasomes and pathogens—sensing of microbes by the inflammasome. EMBO Mol Med 5:814–826
Tian X, Pascal G, Monget P (2009) Evolution and functional divergence of NLRP genes in mammalian reproductive systems. BMC Evol Biol 9:202
Boyden ED, Dietrich WF (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38:240–244
Sastalla I, Crown D, Masters SL, McKenzie A, Leppla SH, Moayeri M (2013) Transcriptional analysis of the three Nlrp1 paralogs in mice. BMC Genomics 14:188
Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O’Donnell JA et al (2012) NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 37:1009–1023
Moayeri M, Crown D, Newman ZL, Okugawa S, Eckhaus M, Cataisson C et al (2010) Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog 6:e1001222
Terra JK, Cote CK, France B, Jenkins AL, Bozue JA, Welkos SL et al (2010) Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J Immunol 184:17–20
Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462:199–204
Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD et al (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734–737
Chavarria-Smith J, Vance RE (2013) Direct proteolytic cleavage of NLRP1B is necessary and sufficient for inflammasome activation by anthrax lethal factor. PLoS Pathog 9:e1003452
Hett EC, Slater LH, Mark KG, Kawate T, Monks BG, Stutz A et al (2013) Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat Chem Biol 9:398–405
Guey B, Bodnar M, Manie SN, Tardivel A, Petrilli V (2014) Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci U S A 111:17254–17259
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P et al (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514:187–192
Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J et al (2011) Non-canonical inflammasome activation targets caspase-11. Nature 479:117–121
Broz P, Ruby T, Belhocine K, Bouley DM, Kayagaki N, Dixit VM et al (2012) Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 490:288–291
Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S et al (2013) Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341:1246–1249
Knodler LA, Crowley SM, Sham HP, Yang H, Wrande M, Ma C et al (2014) Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe 16:249–256
Aachoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE et al (2013) Caspase-11 protects against bacteria that escape the vacuole. Science 339:975–978
Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA (2013) Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341:1250–1253
Demon D, Vande Walle L, Lamkanfi M (2014) Sensing the enemy within: how macrophages detect intracellular gram-negative bacteria. Trends Biochem Sci 39:574–576
Lage SL, Longo C, Branco LM, da Costa TB, Buzzo Cde L, Bortoluci KR (2014) Emerging concepts about NAIP/NLRC4 inflammasomes. Front Immunol 5:309
Rayamajhi M, Zak DE, Chavarria-Smith J, Vance RE, Miao EA (2013) Cutting edge: mouse NAIP1 detects the type III secretion system needle protein. J Immunol 191:3986–3989
Yang J, Zhao Y, Shi J, Shao F (2013) Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A 110:14408–14413
Kofoed EM, Vance RE (2011) Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477:592–595
Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H et al (2011) The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477:596–600
Qu Y, Misaghi S, Izrael-Tomasevic A, Newton K, Gilmour LL, Lamkanfi M et al (2012) Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 490:539–542
Matusiak M, Van Opdenbosch N, Vande Walle L, Sirard JC, Kanneganti TD, Lamkanfi M (2015) Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5. Proc Natl Acad Sci U S A 112:1541–1546
Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A et al (2010) Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 11:1136–1142
Ceballos-Olvera I, Sahoo M, Miller MA, Del Barrio L, Re F (2011) Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1beta is deleterious. PLoS Pathog 7:e1002452
Warren SE, Armstrong A, Hamilton MK, Mao DP, Leaf IA, Miao EA et al (2010) Cutting edge: cytosolic bacterial DNA activates the inflammasome via Aim2. J Immunol 185:818–821
Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L et al (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 11:395–402
Wu J, Fernandes-Alnemri T, Alnemri ES (2010) Involvement of the AIM2, NLRC4, and NLRP3 inflammasomes in caspase-1 activation by Listeria monocytogenes. J Clin Immunol 30:693–702
Sauer JD, Witte CE, Zemansky J, Hanson B, Lauer P, Portnoy DA (2010) Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe 7:412–419
Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J et al (2010) The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 11:385–393
Xu H, Yang J, Gao W, Li L, Li P, Zhang L et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513:237–241
Gavrilin MA, Abdelaziz DH, Mostafa M, Abdulrahman BA, Grandhi J, Akhter A et al (2012) Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol 188:3469–3477
Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) The hereditary autoinflammatory disorders uncovered. Autoimmun Rev 13:892–900
Broderick L, De Nardo D, Franklin BS, Hoffman HM, Latz E (2015) The inflammasomes and autoinflammatory syndromes. Annu Rev Pathol 10:395–424
Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668
Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 34:755–768
Roldan R, Ruiz AM, Miranda MD, Collantes E (2008) Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine Rev Rhum 75:504–505
Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41:265–271
Shinkai K, McCalmont TH, Leslie KS (2008) Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 33:1–9
Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108:615–620
Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46:2445–2452
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581–592
Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443–2452
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416–2425
Meng G, Zhang F, Fuss I, Kitani A, Strober W (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30:860–874
Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C et al (2009) Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30:875–887
Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, Hoffman HM (2013) Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 123:4695–4705
Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D et al (2012) Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One 7:e35979
Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA et al (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64:2375–2386
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y et al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46:1140–1146
Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E, Choi M et al (2014) Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46:1135–1139
Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K (2014) An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211:2385–2396
Hu Z, Yan C, Liu P, Huang Z, Ma R, Zhang C et al (2013) Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science 341:172–175
Luksch H, Romanowski MJ, Chara O, Tungler V, Caffarena ER, Heymann MC et al (2013) Naturally occurring genetic variants of human caspase-1 differ considerably in structure and the ability to activate interleukin-1beta. Hum Mutat 34:122–131
Lamkanfi M, Kalai M, Saelens X, Declercq W, Vandenabeele P (2004) Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J Biol Chem 279:24785–24793
Heymann MC, Winkler S, Luksch H, Flecks S, Franke M, Russ S et al (2014) Human procaspase-1 variants with decreased enzymatic activity are associated with febrile episodes and may contribute to inflammation via RIP2 and NF-kappaB signaling. J Immunol 192:4379–4385
Olson JK, Miller SD (2009) The innate immune response affects the development of the autoimmune response in Theiler’s virus-induced demyelinating disease. J Immunol 182:5712–5722
Shaw PJ, McDermott MF, Kanneganti TD (2011) Inflammasomes and autoimmunity. Trends Mol Med 17:57–64
Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C et al (2009) Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat Genet 41:71–76
Tamura K, Fukuda Y, Sashio H, Takeda N, Bamba H, Kosaka T et al (2002) IL18 polymorphism is associated with an increased risk of Crohn’s disease. J Gastroenterol 37:111–116
Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB et al (2010) The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207:1045–1056
Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD (2010) The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32:379–391
Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y et al (2011) NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 17:1359–1372
Lebeis SL, Powell KR, Merlin D, Sherman MA, Kalman D (2009) Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 77:604–614
Takagi H, Kanai T, Okazawa A, Kishi Y, Sato T, Takaishi H et al (2003) Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand J Gastroenterol 38:837–844
Carvalho FA, Nalbantoglu I, Aitken JD, Uchiyama R, Su Y, Doho GH et al (2012) Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol 5:288–298
Demon D, Kuchmiy A, Fossoul A, Zhu Q, Kanneganti TD, Lamkanfi M (2014) Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Mucosal Immunol 7:1480–1491
Williams TM, Leeth RA, Rothschild DE, McDaniel DK, Coutermarsh-Ott SL, Simmons AE et al (2015) Caspase-11 attenuates gastrointestinal inflammation and experimental colitis pathogenesis. Am J Physiol Gastrointest Liver Physiol 308:G139–150
Oficjalska K, Raverdeau M, Aviello G, Wade SC, Hickey A, Sheehan KM et al (2015) Protective role for caspase-11 during acute experimental murine colitis. J Immunol 194:1252–1260
Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–292
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC (2014) Biologics in Rheumatoid Arthritis G, et al. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73:1202–1210
Yang CA, Huang ST, Chiang BL (2014) Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population. Scand J Rheumatol 43:146–152
Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev CD005121
Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P et al (2014) Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512:69–73
Pontillo A, Brandao L, Guimaraes R, Segat L, Araujo J, Crovella S (2010) Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 43:583–589
Pontillo A, Girardelli M, Kamada AJ, Pancotto JA, Donadi EA, Crovella S et al (2012) Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 45:271–278
Kahlenberg JM, Kaplan MJ (2014) The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol 26:475–481
Magitta NF, Boe Wolff AS, Johansson S, Skinningsrud B, Lie BA, Myhr KM et al (2009) A coding polymorphism in NALP1 confers risk for autoimmune Addison’s disease and type 1 diabetes. Genes Immun 10:120–124
Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S (2013) AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J Clin Immunol 33:925–937
Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y et al (2013) NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome. Proc Natl Acad Sci U S A 110:2952–2956
Jin Y, Birlea SA, Fain PR, Spritz RA (2007) Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 127:2558–2562
Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC et al (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356:1216–1225
Zurawek M, Fichna M, Januszkiewicz-Lewandowska D, Gryczynska M, Fichna P, Nowak J (2010) A coding variant in NLRP1 is associated with autoimmune Addison’s disease. Hum Immunol 71:530–534
Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64:630–633
Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F (2005) Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev 4:542–548
Voronov E, Dayan M, Zinger H, Gayvoronsky L, Lin JP, Iwakura Y et al (2006) IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 17:109–116
Kahlenberg JM, Yalavarthi S, Zhao W, Hodgin JB, Reed TJ, Tsuji NM et al (2014) An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheum 66:152–162
Lech M, Lorenz G, Kulkarni OP, Grosser MO, Stigrot N, Darisipudi MN et al (2014) NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-beta receptor signalling. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-205496
Aksentijevich I, DP C, Remmers EF, Mueller JL, Le J, Kolodner RD et al (2007) The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 56:1273–1285
Neven B, Prieur AM, Quartier dit Maire P (2008) Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 4:481–489
Russo RA, Melo-Gomes S, Lachmann HJ, Wynne K, Rajput K, Eleftheriou D et al (2014) Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology (Oxford) 53:665–670
Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL et al (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779–1785
Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34:2091–2103
de Koning HD, van Gijn ME, Stoffels M, Jongekrijg J, Zeeuwen PL, Elferink MG et al (2014) Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol. doi:10.1016/j.jaci.2014.07.050
Lipsker D (2010) The Schnitzler syndrome. Orphanet J Rare Dis 5:38
Dwivedi M, Laddha NC, Mansuri MS, Marfatia YS, Begum R (2013) Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population. Br J Dermatol 169:1114–1125
Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B et al (2014) Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol 170:816–823
Alkhateeb A, Jarun Y, Tashtoush R (2013) Polymorphisms in NLRP1 gene and susceptibility to autoimmune thyroid disease. Autoimmunity 46:215–221
Grishman EK, White PC, Savani RC (2012) Toll-like receptors, the NLRP3 inflammasome, and interleukin-1beta in the development and progression of type 1 diabetes. Pediatr Res 71:626–632
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381:1905–1915
Schott WH, Haskell BD, Tse HM, Milton MJ, Piganelli JD, Choisy-Rossi CM et al (2004) Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 53:99–104
Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM et al (2010) Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32:367–378
Kastbom A, Verma D, Eriksson P, Skogh T, Wingren G, Soderkvist P (2008) Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology 47:415–417
Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S et al (2014) Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73:1202–1210
Goldbach-Mansky R (2009) Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci 1182:111–123
Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M et al (2011) A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 43:908–912
Kimkong I, Avihingsanon Y, Hirankarn N (2009) Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus 18:1066–1072
Acknowledgments
H.V.G. is a postdoctoral fellow with the Research Foundation Flanders (FWO grant 1.2.449.13 N). Work in ML’s laboratory is supported by grants from VIB, Ghent University (BOF 01 N02313, BOF 01 J11113, BOF14/GOA/013), the Fund for Scientific Research-Flanders (grants G030212N and G011315N), and the European Research Council (grant 281600).
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is a contribution to the Special Issue on The Inflammasome and Autoinflammatory Diseases - Guest Editors: Seth L. Masters, Tilmann Kallinich and Seza Ozen
Pedro H. V. Saavedra and Dieter Demon contributed equally to this work.
Rights and permissions
About this article
Cite this article
Saavedra, P.H.V., Demon, D., Van Gorp, H. et al. Protective and detrimental roles of inflammasomes in disease. Semin Immunopathol 37, 313–322 (2015). https://doi.org/10.1007/s00281-015-0485-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00281-015-0485-5